Get the Stockscreener App
12.38
4.81%
-0.625
After Hours:
16.14
3.765
+30.42%
Anaptysbio Inc Stock (ANAB) Latest News
Anaptys to Announce Top-line Data from Phase 2b Trial of - GlobeNewswire
Major Rheumatoid Arthritis Treatment Breakthrough? AnaptysBio's Phase 2b Trial Results Set to Reshape Treatment Landscape - StockTitan
Ratio Review: Analyzing AnaptysBio Inc (ANAB)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
AnaptysBio (NASDAQ:ANAB) Upgraded by Wolfe Research to Strong-Buy Rating - MarketBeat
Wedbush Weighs in on AnaptysBio's Q1 Earnings (NASDAQ:ANAB) - MarketBeat
AnaptysBio (NASDAQ:ANAB) Now Covered by Wolfe Research - MarketBeat
SG Americas Securities LLC Buys 4,231 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
FY2029 Earnings Estimate for AnaptysBio Issued By Wedbush - MarketBeat
AnaptysBio (NASDAQ:ANAB) Shares Gap UpStill a Buy? - MarketBeat
Weekly Investment Analysts’ Ratings Updates for AnaptysBio (ANAB) - Defense World
AnaptysBio's (ANAB) "Neutral" Rating Reiterated at HC Wainwright - MarketBeat
Wedbush Reiterates "Outperform" Rating for AnaptysBio (NASDAQ:ANAB) - MarketBeat
Check Out AnaptysBio Inc (ANAB)’s Trade Data Rather Than the Analysts’ Views - SETE News
Wolfe Research Begins Coverage on AnaptysBio (NASDAQ:ANAB) - Defense World
AnaptysBio (NASDAQ:ANAB) Upgraded at Wolfe Research - Defense World
Wedbush Predicts AnaptysBio’s Q1 Earnings (NASDAQ:ANAB) - Defense World
H.C. Wainwright maintains AnaptysBio stock Neutral rating, $19 target - MSN
BlackRock, Inc.'s Strategic Acquisition of AnaptysBio Inc Shares - GuruFocus.com
Shareholders in AnaptysBio (NASDAQ:ANAB) are in the red if they invested three years ago - Yahoo Finance
Wolfe Research Initiates Coverage of AnaptysBio (ANAB) with Outperform Recommendation - MSN
What is Wedbush’s Estimate for AnaptysBio FY2029 Earnings? - Defense World
D.C. biotech Vanda Pharmaceuticals acquires AnaptysBio’s drug for rare skin disorder - The Business Journals
AnaptysBio initiated with an Outperform at Wolfe Research - MSN
Analytical Overview: AnaptysBio Inc (ANAB)’s Ratios Tell a Financial Story - The Dwinnex
Correction: Wolfe Initiates Coverage on AnaptysBio With Outperform Rating, $25 Price Target - Marketscreener.com
Analyzing AnaptysBio Inc (ANAB) After Recent Trading Activity - Knox Daily
(ANAB) Investment Analysis - Stock Traders Daily
Analyst Expectations For AnaptysBio's Future - Benzinga
Vanda and AnaptysBio link for generalised pustular psoriasis therapy - Pharmaceutical Technology
AnaptysBio (NASDAQ:ANAB) Given “Outperform” Rating at Wedbush - Defense World
Vanda Pharmaceuticals and Anaptys sign license agreement for imsidolimab - MSN
Anaptys to Present at the Guggenheim SMID Cap Biotech Conference - The Manila Times
AnaptysBio Leadership Shares Strategic Vision at Major Biotech Investment Conference - StockTitan
Vanda, Anaptys Join on Development Pact - Baystreet.ca
Vanda & AnaptysBio Partner for the Development and Commercialization of Imsidolimab - Contract Pharma
AnaptysBio Partners with Vanda for Imsidolimab Development - TipRanks
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab - Marketscreener.com
Vanda Pharmaceuticals, AnaptysBio Sign Global License Agreement for Imsidolimab - Marketscreener.com
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global Lice - GuruFocus.com
Vanda Pharmaceuticals and AnaptysBio to develop and market imsidolimab - TipRanks
AnaptysBio, Vanda announce exclusive global license agreement for Vanda - TipRanks
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist - TradingView
Breakthrough GPP Treatment Deal: Vanda Secures Phase 3-Ready Rare Disease Drug for $15M Upfront - StockTitan
Indo-Asian News Service - IANS India Pvt Ltd
AnaptysBio (NASDAQ:ANAB) Trading Down 4.5%Should You Sell? - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year? - Yahoo Finance
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Acquired by JPMorgan Chase & Co. - MarketBeat
JPMorgan Chase & Co. Increases Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
Objective long/short (ANAB) Report - Stock Traders Daily
Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - Benzinga
Assenagon Asset Management S.A. Cuts Position in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
Assenagon Asset Management S.A. Decreases Position in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
2.27%
5.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):